Perspective: Bioorthogonal Nanoclear System: An Enhanced Multi-Modal Nanotherapeutic Strategy for Targeted Reversal of Sepsis Pathologies
Fuente:
Zenodo
Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2026
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901480385019904 |
|---|---|
| author | Shibah, Sami Rashid Mohammed |
| author_facet | Shibah, Sami Rashid Mohammed |
| contents | <p>Purpose: Sepsis, characterized by dysregulated immune responses to infection, poses a significant global health challenge with approximately 49 million cases and 11 million deaths annually as of 2020 (rudd2020). Despite advances in antimicrobial therapy, the heterogeneous pathophysiology of sepsis necessitates innovative multi-modal interventions. This perspective proposes an enhanced Bioorthogonal Nanoclear (BON) system, a hybrid pH-responsive nanotechnology platform utilizing poly(lactic-co-glycolic acid) (PLGA) nanoparticles with pH-labile modifications for targeted sequestration of inflammatory mediators, immunomodulation, and endothelial stabilization to mitigate sepsis pathologies, while addressing key limitations such as protein corona effects and endotype heterogeneity.<br>Methods: The BON system employs copper-free azide-alkyne cycloaddition for surface functionalization with high-affinity ligands targeting pathogen-associated molecular patterns (PAMPs; e.g., Pep19-2.5 for lipopolysaccharide [LPS], Kd ∼ 10^{-9} M (correa2019,brandenburg2021)) and damage-associated molecular patterns (DAMPs; e.g., low-molecular-weight heparin derivatives for high-mobility group box 1 [HMGB1], Kd ∼ 0.3-8 × 10^{-9} M (milev1998)). The hybrid PLGA core (50:50 lactide:glycolide, molecular weight 30--60 kDa, 100--200 nm diameter, with hydrazone or acetal linkers) encapsulates interleukin-10 (IL-10) inducers (IT-9302 analogs, encapsulation efficiency >80%) and sphingosine-1-phosphate (S1P) for pH-triggered release at septic sites (pH 6.5--6.9, ∼80% release within 12 hours, with batch variability ±15%). Design parameters are derived from literature, with in silico modeling of pharmacokinetics (compartmental analysis: C(t) = C0 e^{-kt}, k ≈ 0.03 h^{-1}) and release kinetics (Peppas equation: Mt/M∞ = k t^n, n ≈ 0.43). Falsifiable hypotheses for preclinical validation in murine cecal ligation and puncture (CLP) models are outlined, supported by advanced quantitative systems pharmacology (QSP) simulations incorporating nonlinear dynamics and endotype stratification.<br>Results: Hypothetical outcomes, based on Monte Carlo simulations (mean sequestration 70.7%, probability >60%: 85%), predict 60--80% sequestration of LPS/HMGB1 in vitro (ELISA, n=6, p<0.05), pH-dependent release profiles minimizing off-target effects (<10% at pH 7.4), and 30--50% survival improvement in CLP models (n=20/group, log-rank p<0.05), stratified by hyper- vs. hypo-inflammatory endotypes. Pilot in vitro experiments (data in preparation) confirmed >75% LPS/HMGB1 sequestration and >70% payload release at pH 6.5 in septic plasma (ELISA, n=6, p<0.01). Integration with recent nanomedicine advances, such as neutrophil-targeted nanoparticles (huang2025), bioorthogonal recruitment systems (peng2025), gold nanoclusters for cytokine storm attenuation (wen2025), and maca-derived lipid nanoparticles leveraging protein corona for anti-inflammatory effects (sung2025,sung2024), enhances translational potential (liu2025,louaguenouni2025,khosravi2025).<br>Conclusion: The enhanced BON system represents a potentially transformative multi-modal therapeutic framework for sepsis, addressing inflammatory triggers, immune dysregulation, and vascular integrity with high specificity and reduced toxicity, while incorporating strategies to mitigate protein corona and adapt to sepsis heterogeneity. As a conceptual framework, limitations include reliance on extrapolated data and lack of empirical validation; rigorous preclinical and clinical studies, including pilot in vitro assays and endotype-specific trials, are essential to confirm efficacy, safety, and overcome translational barriers.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18866145 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Perspective: Bioorthogonal Nanoclear System: An Enhanced Multi-Modal Nanotherapeutic Strategy for Targeted Reversal of Sepsis Pathologies Shibah, Sami Rashid Mohammed <p>Purpose: Sepsis, characterized by dysregulated immune responses to infection, poses a significant global health challenge with approximately 49 million cases and 11 million deaths annually as of 2020 (rudd2020). Despite advances in antimicrobial therapy, the heterogeneous pathophysiology of sepsis necessitates innovative multi-modal interventions. This perspective proposes an enhanced Bioorthogonal Nanoclear (BON) system, a hybrid pH-responsive nanotechnology platform utilizing poly(lactic-co-glycolic acid) (PLGA) nanoparticles with pH-labile modifications for targeted sequestration of inflammatory mediators, immunomodulation, and endothelial stabilization to mitigate sepsis pathologies, while addressing key limitations such as protein corona effects and endotype heterogeneity.<br>Methods: The BON system employs copper-free azide-alkyne cycloaddition for surface functionalization with high-affinity ligands targeting pathogen-associated molecular patterns (PAMPs; e.g., Pep19-2.5 for lipopolysaccharide [LPS], Kd ∼ 10^{-9} M (correa2019,brandenburg2021)) and damage-associated molecular patterns (DAMPs; e.g., low-molecular-weight heparin derivatives for high-mobility group box 1 [HMGB1], Kd ∼ 0.3-8 × 10^{-9} M (milev1998)). The hybrid PLGA core (50:50 lactide:glycolide, molecular weight 30--60 kDa, 100--200 nm diameter, with hydrazone or acetal linkers) encapsulates interleukin-10 (IL-10) inducers (IT-9302 analogs, encapsulation efficiency >80%) and sphingosine-1-phosphate (S1P) for pH-triggered release at septic sites (pH 6.5--6.9, ∼80% release within 12 hours, with batch variability ±15%). Design parameters are derived from literature, with in silico modeling of pharmacokinetics (compartmental analysis: C(t) = C0 e^{-kt}, k ≈ 0.03 h^{-1}) and release kinetics (Peppas equation: Mt/M∞ = k t^n, n ≈ 0.43). Falsifiable hypotheses for preclinical validation in murine cecal ligation and puncture (CLP) models are outlined, supported by advanced quantitative systems pharmacology (QSP) simulations incorporating nonlinear dynamics and endotype stratification.<br>Results: Hypothetical outcomes, based on Monte Carlo simulations (mean sequestration 70.7%, probability >60%: 85%), predict 60--80% sequestration of LPS/HMGB1 in vitro (ELISA, n=6, p<0.05), pH-dependent release profiles minimizing off-target effects (<10% at pH 7.4), and 30--50% survival improvement in CLP models (n=20/group, log-rank p<0.05), stratified by hyper- vs. hypo-inflammatory endotypes. Pilot in vitro experiments (data in preparation) confirmed >75% LPS/HMGB1 sequestration and >70% payload release at pH 6.5 in septic plasma (ELISA, n=6, p<0.01). Integration with recent nanomedicine advances, such as neutrophil-targeted nanoparticles (huang2025), bioorthogonal recruitment systems (peng2025), gold nanoclusters for cytokine storm attenuation (wen2025), and maca-derived lipid nanoparticles leveraging protein corona for anti-inflammatory effects (sung2025,sung2024), enhances translational potential (liu2025,louaguenouni2025,khosravi2025).<br>Conclusion: The enhanced BON system represents a potentially transformative multi-modal therapeutic framework for sepsis, addressing inflammatory triggers, immune dysregulation, and vascular integrity with high specificity and reduced toxicity, while incorporating strategies to mitigate protein corona and adapt to sepsis heterogeneity. As a conceptual framework, limitations include reliance on extrapolated data and lack of empirical validation; rigorous preclinical and clinical studies, including pilot in vitro assays and endotype-specific trials, are essential to confirm efficacy, safety, and overcome translational barriers.</p> |
| title | Perspective: Bioorthogonal Nanoclear System: An Enhanced Multi-Modal Nanotherapeutic Strategy for Targeted Reversal of Sepsis Pathologies |
| url | https://doi.org/10.5281/zenodo.18866145 |